Breaking News, Collaborations & Alliances

HAS Group, Biodelphis Therapeutics Partner to Advance Antibody Protease Inhibitor Conjugates

The collaboration combines HAS Group’s expertise in complex bioconjugation, process development, and clinical-grade manufacturing with Biodelphis Therapeutics’ APIC platform.

Author Image

By: Charlie Sternberg

Associate Editor

HAS Healthcare Advanced Synthesis and Biodelphis Therapeutics have signed a strategic agreement to support the development and GMP manufacturing of Antibody Protease Inhibitor Conjugates, an emerging class of targeted therapeutics designed to selectively inhibit disease-driving proteases. This collaboration combines HAS Group’s expertise in complex bioconjugation, process development, and clinical-grade manufacturing with Biodelphis Therapeutics’ APIC platform, a novel drug modality engineere...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters